DFG

Funding will go to the West German Genome Center, the NGS Competence Center Tübingen, the Dresden-Concept Genome Center, and the Competence Center for Genomic Analysis Kiel.

NEW YORK (GenomeWeb News) – Mainz University said today that the German Research Foundation (DFG) has awarded €1.5 million ($2 million) to an investigator to establish a research group at Mainz's Institute of Molecular Biology that will use proteomics technologies to study DNA damage and repair,

NEW YORK (GenomeWeb News) – The University Medical Center at Johannes Gutenberg University Mainz in Germany (JGU) announced today separate deals to build out its capabilities in neuroscience research.

The German Research Foundation this week named Matthias Mann one of eleven winners of the 2012 Leibniz Prize for his work in the development of mass spec-based proteomics.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Nine German universities have won a total of €5.8 million ($8.2 million) from the government to buy imaging mass spectrometers for a range of life sciences research applications.

The new center will conduct basic research into the molecular composition and three-dimensional structure of larger multi-protein complexes of biomolecules, with the goal of better understanding their role in living cells, the DFG said in a statement.

Research centers focused on molecular biology and protein splitting are among 12 new 'Collaborative Research Centres.'

Researchers from four institutions will use an RNAi screen to identify genes involved in the development of the red brown flour beetle.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.